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Tumor formation and maintenance depend on a small fraction of cancer stem cells (CSCs) that can self-
renew and generate a wide variety of differentiated cells. CSCs are resistant to chemotherapy and ra-
diation, and can represent a reservoir of cancer cells that often cause relapse after treatment. Evidence
suggests that CSCs also give rise to metastases. Thyroid hormone (TH) controls a variety of biological
processes including the development and functioning of most adult tissues. Recent years has seen the
emergence of an intimate link between TH and multiple steps of tumorigenesis. Thyroid hormone
controls the balance between the proliferation and differentiation of CSCs, and may thus be a druggable
anti-cancer agent. Here, we review current understanding of the effects of TH on colorectal CSCs,
including the cross regulatory loops between TH and regulators of CSC stemness. Targeting TH in the
tumor microenvironment may improve treatment strategies.
© 2017 Published by Elsevier Ireland Ltd.1. Introduction
1.1. Thyroid hormone, deiodinases and cancer
Thyroid hormone (TH) regulates a wide variety of cellular pro-
cesses in vertebrates, including cellular proliferation, differentia-
tion and apoptosis, by inﬂuencing the expression of different sets of
genes (Gereben et al., 2008; Dentice and Salvatore, 2011). Most TH
actions are initiated by the binding of T3 to its nuclear receptors in
target cells (Yen, 2001; Mullur et al., 2014), which results in TH-
dependent transcriptional activation or repression (Wu et al.,
2001; Yen et al., 2006). Apart from this genomic action of TH,
part of TH signal is also mediated via a non-genomic action
involving binding of TRs with different cytosolic partners (Brent,
2012). The biological activity of TH is determined largely by the
intracellular concentration of T3, which, in turn, depends on the
deiodinases that catalyze the production (D1 and D2) or degrada-
tion (D3) of T3 (Visser, 2016). Indeed, despite the relatively constant
TH plasma levels, TH signaling in individual tissues can signiﬁcantly
change consequent to local TH metabolism mediated by iodothyr-
onine deiodinase (Dentice et al., 2013a). Several studies indicateicine and Surgery, University
, Italy.
ice).that TH is closely linked to neoplastic transformation (Dentice et al.,
2013b).
The expression of the deiodinases is often altered in cancer
(Table 1). In fact, D1 expression was found to be lower in kidney
cancer cells than in their normal counterparts (Pachucki et al.,
2001), and signiﬁcantly lower in lung cancer than in normal tis-
sue (Wawrzynska et al., 2003). On the contrary, D1 expression and
activity was found to be higher in breast cancer and in the breast
cancer cell line MCF-7 than in controls (Macejova et al., 2001;
Debski et al., 2007). A similar pattern occurs in thyroid cancer
where, depending on the subtype and histological characteristics,
D1 is expressed both in the tumor and in normal tissue (Schreck
et al., 1994; de Souza Meyer et al., 2005). A very recent study
demonstrated that loss of Dio1 contributes to renal carcinogenesis,
while induction of D1 expression inhibits proliferation and
migration of renal cancer cells (Poplawski et al., 2017). D2 is over-
expressed in most brain tumors, namely, astrocytomas, glioblas-
tomas, gliosarcomas and oligodendrogliomas (Mori et al., 1993;
Nauman et al., 2004), while down-regulated in pituitary tumors
(Piekielko-Witkowska et al., 2013), and in papillary thyroid carci-
noma (Arnaldi et al., 2005; Murakami et al., 2001). Notably, it is
expressed in human osteoblast cells as well as in osteosarcoma cells
(SaOS-2), suggesting that D2 is essential not only for osteoblast
homeostasis but also for neoplastic transformation (Gouveia et al.,
2005; Morimura et al., 2005). A recent study demonstrated that D2
is expressed in basal-cell carcinoma (BCC) in which D2 inactivation
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A.G. Cicatiello et al. / Molecular and Cellular Endocrinology 459 (2017) 84e89 85accelerates cell cycle progression thereby enhancing the proportion
of S-phase cells and cyclin D1 expression and reducing basal
apoptosis (Miro et al., 2017).
The deiodinase that has been most frequently associated with
mouse and human carcinogenesis is D3, which is in line with its
deﬁnition as an oncofetal protein (Dentice, 2011). This observation
suggests a link between deiodinase-mediated TH attenuation and
tumorigenesis. Indeed, immortalized cell lines derived from BCCs,
hemangiomas, hepatocarcinomas, breast cancer (MCF-7 cells), co-
lon adenocarcinomas (Caco2, SW480, and HCT116 cells), thyroid
cancer, endometrium cancer (ECC-1 cells), and neuroblastoma (SH-
SY5Y cells) express elevated D3 levels (Huang et al., 2000; Kester
et al., 2006; Dentice et al., 2009; Sibilio et al., 2012). D3 is also
overexpressed in many human solid tumors, namely, vascular tu-
mors, hepatic hemangiomas and colon carcinomas (Dentice et al.,
2013b). Notably, D3 expression in colon cancer is signiﬁcantly
higher than in normal tissues but negatively correlated with the
histologic grade of the lesions, which suggests that D3 could be an
early marker of tumorigenesis.
Also TH receptor (TR) availability affects tumorigenesis as
demonstrated by the ﬁnding that the v-erbA oncogene isolated
from an avian retrovirus is a mutated form of the human TRa
(Table 2), (Sap et al., 1986; Weinberger et al., 1986). Further evi-
dence implicating TRs in cancer comes from studies showing that
loss of heterozygosity is a frequent event in breast (Futreal et al.,
1992), prostate (Gao et al., 1995) and gastrointestinal cancer
(Huber-Gieseke et al., 1997). One of the most widely used mouse
models created for studies of the role of TRs in cancer trans-
formation, is the ThrbPV/PV mutant. This mouse has a single base
insertion (cytosine) that leads to a frameshift in the C-terminal 14
amino acids of TRb, and ends with the addition of 2 amino acids in
the receptor's polypeptide chain (Kaneshige et al., 2000). These
mice spontaneously develop follicular thyroid cancer (Lu et al.,
2012) and mammary tumors (Guigon et al., 2011). Moreover,
several TR mutations are frequent in hepatocellular carcinoma
(Chen et al., 2008; Chan and Privalsky, 2009), thyroid cancer (Yen
and Cheng, 2003) and renal clear cell carcinoma (Rosen and
Privalsky, 2009).
1.2. Thyroid hormone and stem cells
Given TH's critical role as a regulator of the balance between cell
proliferation and differentiation (Dentice et al., 2013a), it is not
surprising that the self-renewal and speciﬁcation of stem/progen-
itor cells are highly sensitive to TH action. The neural stem cell
niche is regulated by TH and by the TRa1 receptor, which affect the
decision of neural stem cells to self-renew and/or differentiate, so
giving rise to different progenitor cells, i.e., neurons, oligodendro-
cytes, and astrocytes (Lopez-Juarez et al., 2012). Similarly, the dy-
namic control of the TH signal by deiodinases D2 and D3 is
exploited by muscle stem cells to ﬁnely regulate ampliﬁcation and
differentiation during the linear progression of satellite cells
(Dentice et al., 2014; Salvatore et al., 2014). Importantly, the dif-
ferential expression of the deiodinases during myogenesis is
epigenetically controlled through the combined action of a tran-
scriptional machinery involving the DNA methyltransferase en-
zymes as well as muscle-speciﬁc transcriptional factors (Ambrosio
et al., 2013). In the intestinal epithelium, the TRa1 receptor regu-
lates the fate of precursor cells and crypt proliferation by inter-
acting with the Wnt and Notch pathway (Kress et al., 2010; Sirakov
et al., 2012, 2015). In particular, Sirakov et al. have demonstrated
that the TH-TRa1 complex positively regulates the Notch signaling
and the Notch downstream targets in mouse intestinal crypts, thus
in turn resulting in altered proliferation/differentiation balance
(Sirakov et al., 2015). Considering the intimate links between Notch
Table 2
Mutations of thyroid hormone receptors (TRs) in tumors.
TRa TRb
Tumor Mutation Ref. Tumor Mutation Ref.
Breast cancer LOH Gao et al., 1995 Breast cancers LOH Huber-Gieseke et al., 1997
TSHoma H435Y;
TRb2 aberrant
alternative -
splicing
Rosen and Privalsky, 2009 Small cell lung cancers LOH Huber-Gieseke et al., 1997
Hepatocellular carcinoma K74E; K74R;
M150T; E159K;
A264V
Chan and Privalsky, 2009 Gastrointestinal cancer LOH Huber-Gieseke et al., 1997
Non-functioning pituitary adenomas S45I;
L370N;
S377L
Rosen and Privalsky, 2009 Hepatocellular carcinoma M32I;C207R;
T368N; S43L;
C446R; M313I;
K113N; T329P
Chan and Privalsky, 2009
Papillary thyroid carcinoma T80I; L109P;
E213D; S305P;
K337R; G57E;
K29T; C97Xa;
Y352C; S183N;
H184Q; Q187Xa;
R228H; E245V;
K288E; S183N;
H184Q; R228H;
M369V; S183N;
H184Q; R228H;
S271I
Rosen and Privalsky, 2009 Papillary thyroid carcinoma M32V; E34G;
P141L; A318D;
F451I; N76D;
S81L; I135V;
Q136H;
R201Xa
F403L; C446R;
K91R; K289M;
Q235X; M379T;
D427G; K411E;
Q205L; K103R;
M32T; L373P;
K411E; H435R;
S99R
Rosen and Privalsky, 2009
Renal clear cell carcinoma S183N; H184Q;
R228H; K288E;
I116N; M388I;
I116N; A225T;
M388I
Rosen and Privalsky, 2009 Renal clear cell carcinoma S99R; W219L;
F451I; Y321H;
F451S; Q252R;
A387P; F417L;;
K155E; K411E;
D1-26; S380F
Rosen and Privalsky, 2009
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the intriguing possibility that THmight be involved in the control of
CSC behavior, and that the TH signal might be a critical component
of the CSC compartment.
This Review focuses on the evolving concept that the TH signal
plays a role in CSC biology. Particular emphasis is placed on recent
studies showing how the plastic control of TH by D2 and D3
drastically affects the differentiation of CSCs thereby inﬂuencing
their sensitivity to conventional therapies (Graphical Abstract). The
ﬁnding that TH reduces the tumorigenesis of some cancer types by
acting not only on the tumor mass, but also on CSCs has reinforced
the concept that TH may be a tool with which to manipulate the
cancer stem cell pool in tumors.
2. Two established D3-dependent tumors: BCC and colon
cancer
D3 has been consistently found in many hyperproliferative
conditions as well as in cancer cells and tumors (Dentice et al.,
2013b; Dentice, 2011). A functional link has been demonstrated
between D3 expression, TH attenuation and tumorigenesis in two
examples of epithelial tumorigenesis (BCC and colon cancer)
(Dentice et al., 2007, 2012). Basal cell carcinoma is the most
frequently diagnosed human cancer and accounts for approxi-
mately 80% of all non-melanoma skin cancers. In BCC-derived cells
and in BCC solid tumors, D3 is under the control of the Shh-Gli2
cascade (Dentice, 2011). By directly inducing D3 in keratinocytes,
Shh causes a hypothyroid state at intracellular level that increases
the proliferative rate. D3 expression in BCC cells determines a
proliferative advantage for the tumor and, conversely, D3-depletion
attenuates tumorigenesis and enhances the apoptotic process.
Moreover, T3 treatment or D3-depletion reduces tumor growth bypromoting Gli degradation and Shh pathway inhibition (Luongo
et al., 2014). Additionally, it was recently demonstrated that D3 is
also controlled by the cancer-associated microRNA-21 in BCC and
that a reciprocal regulation between TH action and miR21 is
essential for BCC formation (Di Girolamo et al., 2016).
Colorectal cancer (CRC) is one of the most common and lethal
tumors worldwide. Given the high regenerative and proliferative
nature of the intestinal epithelium, it is not surprising that the in-
testinal system provides enormous opportunities for the accumu-
lation of genetic mutations (Markowitz and Bertagnolli, 2009;
Lampropoulos et al., 2012). In fact, the tumorigenesis of CRC is a
multi-step process in which over 90% of cancers originate from
activating mutations in the Wnt pathway (Beck and Blanpain,
2013). In colon cancer stem cells (CR-CSCs) dual D2-D3 expres-
sion is tightly regulated by the Wnt/b-catenin pathway (Dentice
et al., 2012). Speciﬁcally, the TH-activating D2 enzyme is down-
regulated by b-catenin, whereas D3 is a direct target of b-catenin
that binds to the D3 promoter and activates D3 transcription. The
result of this dual regulation is a potent reduction of intracellular T3
induced by the Wnt pathway in the formation of colon cancer.
Alterations of this mechanism perturb tumorigenesis as demon-
strated by the ﬁnding that D3-depletion and T3 treatment increase
E-cadherin expression, and reduce nuclear translocation of b-cat-
enin, thereby resulting in cell differentiation and reduced cellular
proliferation. Collectively, these two examples of epithelial
tumorigenesis indicate that multiple oncogenic signals concur to
reduce the TH environment in the tumor context.
Notably, regulation of intracellular T3 concentrations can now
be added to the list of extrinsic factors that could be exploited to
therapeutically modulate, in a locally restricted fashion, the action
of TH in TH-sensitive tumors.
A.G. Cicatiello et al. / Molecular and Cellular Endocrinology 459 (2017) 84e89 873. Colon cancer stem cells
The cell of origin of colorectal cancer is unknown, but various
models have been proposed to explain the growth and heteroge-
neity of the tumor. According to the CSC theory, the ﬁrst mutation
occurs in a colonic stem cell. Throughout their life, CSCs continue to
accumulate oncogenic mutations and start to divide symmetrically
and asymmetrically thus giving rise to other CSCs and progenitors
(Boman and Huang, 2008). Based on the spontaneous lineage
progression of intestinal stem cells toward the crypt-villus axis, two
alternative models, namely, “top-down” and “bottom-up”, have
been proposed for the histogenesis of CRC. According to the top-
down model, the more differentiated (luminal) cells re-acquire
stem cell-like properties and produce aberrant crypt foci where
tumors develop. Conversely, the bottom-up hypothesis suggests
that stem cells at the base of the crypt base amplify and migrate
upwards, thus constituting tumor-initiating cells (Zeuner et al.,
2014; Basu et al., 2016). In both models, Wnt/b-catenin signaling
is considered a master inducer of colon CSC biogenesis, which is in
agreement with the concept that nearly 90% of colon cancers have
mutations in the same signaling pathway (Boman and Huang,
2008). Indeed, Dow and colleagues demonstrated that suppres-
sion of antigen-presenting cells (APC) results in the development of
colon cancer in mice, while re-expression of APC in these tumors
down-grow the tumorigenic lesions, even in mice harboring
oncogenic Kras and p53 mutations (Dow et al., 2015).
Various speciﬁc markers for the CSC phenotype have been
identiﬁed. Colon CSCs (CR-CSCs) were originally identiﬁed in pri-
mary tumors through their expression of CD133 (O'Brien et al.,
2007; Ricci-Vitiani et al., 2007). CD133 expression was observed
not only in tumor cells, but also in normal colon albeit at a low level.
These results suggest a relation between normal and CSCs.
A second well-established CR-CSC marker is Lgr5, which is a
target gene ofWnt signaling (Barker et al., 2007). Lgr5-positive cells
act as tumor-initiating cells that lead to adenoma formation (Barker
et al., 2009). Moreover, high Lgr5-expressing CRC cells (Lgr5-Hi)
had a greater propensity to expand clonally, while Lgr5 suppression
resulted in the loss of their ability to form colonies (Kemper et al.,
2012). Other CR-CSC markers are Ascl2 and Sox9 (Munoz et al.,
2012), which are also a Wnt target thereby highlighting the
requirement for sustained Wnt signaling for the maintenance of
the stem cell population in colon cancer.
In the last decade, CR-CSCs have been successfully isolated by
FACS sorting from colon cancers by speciﬁc surface epitopes, i.e.,
CD44, CD166, CD133 and ESA (epithelial-speciﬁc antigen, also
known as “EpCAM”) surface markers (Todaro et al., 2014; Dalerba
et al., 2007). These cells represent a dynamic population highly
sensitive to genetic, epigenetic, and micro-environmental factors
(Kreso and Dick, 2014). Consequently, changes in the cell niche can
drastically affect their stemness and resistance to cancer therapy.
4. TH and colon cancer stem cells
One of the most exciting recent ﬁndings about TH in tumori-
genesis is that, not only do TH and deiodinases affect the prolifer-
ation and differentiation of CR-CRCs but that the control of TH in
the tumor microenvironment profoundly affects CSC behavior
(Catalano et al., 2016). Analysis of D2 and D3 expression in different
cell populations of human CR-CSCs demonstrated that D2 and D3
are dynamically expressed by quiescent-versus-differentiated CR-
CSCs. In particular, D3 is potently expressed in undifferentiated CR-
CSCs, inwhich theWnt pathway is very active. Conversely, D2 is up-
regulated in CR-CSCs in parallel with differentiation, which sug-
gests that TH might contribute to stem cell differentiation. Indeed,
TH treatment induces a differentiation program of quiescent CR-CSCs similar to the differentiation effects of serum. As concern
the TRs expression, both TRa and TRb are expressed in human CR-
CSCs (Catalano et al., 2016). Although D3 did not exert transforming
ability per se in normal colon cells, D3 expression is required for
tumor formation and maintenance as demonstrated by the drasti-
cally attenuated clonogenic capacity and tumorigenesis of D3-
depleted colon cancer stem cells (Catalano et al., 2016). Interest-
ingly, the effects of TH and its metabolism are quite different in
CSCs compared to what observed for the adult quiescent stem cells.
For instance, in the intestine epithelium, by positively regulating
Notch signaling, TH and its receptor TRa increases the proliferation
of progenitor cells of the crypt (Sirakov et al., 2015). Conversely, TH
signal ampliﬁcation induces CSCs differentiation (Catalano et al.,
2016). These discrepancies might be due to the different traits
that distinguish CSCs from adult stem cells. For example, while
adult stem cells are quiescent, mitotically dormant cells, the CSCs
for their tumorigenic nature, are more prone to the proliferation.
Identiﬁcation of the differentiative ability of TH on CR-CSCs
raised the question “can TH treatment affect the sensitivity of
these cells to conventional chemotherapy”. Notably, pre-treatment
of CR-CSCs with TH increased cell death induced by the chemo-
therapeutic agents oxaliplatin and 5-ﬂuorouracil (Catalano et al.,
2016). Nearly all the pro-differentiative effects of TH on CR-CSCs
were promoted by regulation of two signaling pathways involved
in the control of stemness and differentiation of intestinal stem
cells, namely the Wnt and BMP pathways. The molecular mecha-
nisms by which TH inﬂuences CR-CSC stemness and differentiation
involve the Wnt and BMP pathways. Indeed, TH treatment en-
hances BMP expression in human CR-CSCs and attenuates the effect
of the Wnt pathway and of a large cohort of Wnt pathway target
genes (Catalano et al., 2016).
Taken together, these data indicate that by inducing differenti-
ation, growth reduction, and chemosensitization of CR-CSCs, the
endocrine signal of TH promotes CSC-depletion in colon cancero-
genesis (Graphical Abstract). The exciting consequences of this
process might be that the combined action of intracellular T3 and
chemotherapy may strengthen colorectal cancer treatment and
open new avenues for the use of tissue-speciﬁc regulation of dei-
odinases for treating cancer.
5. Conclusions
The discovery that cancer is driven by CSCs has attracted a great
deal of attention particularly in view of the potential for the
treatment of solid malignancies. Conventional therapies induce
tumor regression, but fail to effectively target CSCs, leading to
increased risk of relapse. Therefore, in order to prevent tumor
recurrence it is important to develop drugs that can speciﬁcally
target and eliminate CSCs (graphical abstract). Despite advances in
therapeutic strategies, CRCs remain the third leading cause of
cancer-related deaths worldwide, and one of the major reasons for
failing therapies is that treatment strategies were designed to
reduce the mass of the tumor. Colorectal cancer stem cells have
been successfully isolated from human colon carcinomas using
stem cell markers. These cells accounted for approximately 2.5% of
tumor cells; they can induce xenograft tumors in immunocom-
promised mice and can also reconstitute the tumor containing
differentiated cells and the original heterogeneity.
The recently introduced concept that TH and its regulating en-
zymes D2 and D3 are dynamically regulated in different sub-
populations of CR-CSCs according to their stem-like versus
differentiated shape has suggested that the control of intracellular
TH availability might be a tool with which to affect the stemness
and ampliﬁcation potential of these cells. As illustrated in graphical
abstract, thyroid hormone not only induces the differentiation of
A.G. Cicatiello et al. / Molecular and Cellular Endocrinology 459 (2017) 84e8988CR-CSCs, but also attenuates symmetric cancer cell division and
sensitizes these cells to conventional anti-cancer treatments,
thereby overcoming drug resistance. Thyroid hormone controls the
most important pathways involved in the regulation of CR-CSCs:
the WNT, BMP and Notch pathways (Sirakov et al., 2015; Catalano
et al., 2016). By regulating multiple oncogenic pathways, TH
might represent a critical hub that can inﬂuence the CSC
compartment and eliminate symmetric cancer populations.
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